IIIC1r期局部晚期宫颈癌盆腔及主动脉淋巴结转移的拓扑分布:西班牙妇科肿瘤组回顾性研究
该多中心回顾性研究纳入164例IIIC1r期局部晚期宫颈癌患者,术前均行影像学分期及腹腔镜腹膜外主动脉淋巴结清扫至左肾静脉。结果示盆腔淋巴结转移经病理确认者73例(44.5%),其中31例(42.5%)合并主动脉淋巴结转移;盆腔淋巴结阴性96例(58.5%)中11例(11.5%)有主动脉转移。作者认为上肠系膜区病变率支持将预防性延伸野放疗扩展至左肾静脉。
要点
- IIIC1r期患者中,盆腔淋巴结转移经手术病理确认者不足50%(73/164,44.5%)。
- 盆腔淋巴结阳性者主动脉转移率为42.5%(31/73),阴性者亦达11.5%(11/96)。
- 主动脉转移中上肠系膜区受累比例支持延伸野放疗覆盖至左肾静脉。
核心结论
- IIIC1r期局部晚期宫颈癌经手术评估后盆腔淋巴结转移确认率不足50%。
- 盆腔淋巴结转移时主动脉淋巴结受累风险更高,但并非仅见于盆腔阳性者。
- 上肠系膜区病变率支持将预防性延伸野放疗扩展至左肾静脉。
研究设计与样本
- 西班牙妇科肿瘤组开展的多中心回顾性研究。
- 纳入164例FIGO IIIC1r期局部晚期宫颈癌患者。
- 所有患者接受放化疗及治疗前腹腔镜腹膜外主动脉淋巴结清扫至左肾静脉,并对影像学可疑盆腔淋巴结行减瘤术。
- 影像学分期采用MRI和/或PET扫描。
- 淋巴结转移按部位分类为盆腔或主动脉、肠系膜上/下区域。
主要发现
- 96.3%的患者接受MRI评估,35%接受PET扫描。
- 中位切除淋巴结数:主动脉12枚,盆腔8.5枚。
- 盆腔淋巴结转移经病理确认73例(44.5%),其中31例(42.5%)有主动脉转移:肠系膜下区24.7%,肠系膜上区4.1%,两区域均受累13.7%。
- 盆腔淋巴结阴性96例(58.5%),其中11例(11.5%)有主动脉转移:肠系膜下区7.3%,肠系膜上区3.1%,两区域均受累1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lymph node (LN) metastasis is a key prognostic factor in locally advanced cervical cancer (LACC), especially at the aortic level. Prophylactic extended-field radiotherapy (EFRT) indications are being evaluated, as imaging (r) may miss low-volume aortic LN disease in patients with pelvic LN metastasis. Our aim was to describe the distribution of pelvic and aortic LN metastasis confirmed by histology in patients with FIGO stage IIIC1r LACC. METHODS: This multicenter retrospective study included women with FIGO stage IIIC1r LACC treated with chemoradiotherapy and pretherapeutic nodal surgical staging with laparoscopic extraperitoneal aortic lymphadenectomy to the left renal vein and debulking of pathological pelvic LN on imaging. Imaging for stage IIIC1r diagnosis included MRI and/or PET-scan. LN metastasis distribution was categorized by location: pelvic or aortic and supra- or inframesenteric. RESULTS: We included 164 patients, 96.3 % evaluated with MRI and 35 % with PET-scan. The median number of excised LN was 12 aortic and 8.5 pelvic. Pelvic LN metastasis was confirmed in 73 patients (44.5 %), of whom 31 (42.5 %) had aortic LN metastasis: 24.7 % inframesenteric, 4.1 % supramesenteric, and 13.7 % both. Pelvic LN were negative in 96 patients (58.5 %), of whom 11 (11.5 %) had aortic LN metastasis: 7.3 % inframesenteric, 3.1 % supramesenteric, and 1 % both. CONCLUSIONS: In stage IIIC1r LACC, pelvic LN metastasis are confirmed in less than 50 % of patients following surgical evaluation. The risk of aortic LN involvement is higher when there are metastases at the pelvic level but not exclusively. The rate of supramesenteric disease supports extending the EFRT to the left renal vein.
引用
- Acosta Ú, Bebia V, Torné A, et al. Topographic mapping of pelvic and aortic lymph node metastases in stage IIIC1r locally advanced cervical cancer: A retrospective study by the Spain-GOG group. Gynecol Oncol. 2025. PMID: 40414142. doi:10.1016/j.ygyno.2025.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。